Xenon Pharmaceuticals Inc at Stifel CNS Days (Virtual) Transcript
Great. Good morning, everybody. It's my pleasure to be moderating this panel with two members of the Xenon executive team, Ian Mortimer, CEO; and Chris Von Seggern, Chief Commercial Officer. I'm sure most folks know the company well, but maybe I can briefly turn it over to Ian just for some opening remarks, update on 1101, and next steps, and then we can get into Q&A. So thank you again.
Excellent. Thanks, Paul. Good morning, everyone, and thanks, Paul, to you and to Stifel for hosting us this morning. So we're coming off a transformational year in Xenon. You mentioned 1101; we had really strong data last fall and we're building off of that for this year. And I'll come back to some of the next steps in that program in terms of getting it into the Phase 3 program, getting through an end-of-Phase 2 meeting with regulators. And we're on the cusp of starting a study in major depressive disorder as well, so we'll spend some time on that today.
At Xenon
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
